Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume69.06K
Average Volume (3M)180.50K
Market Cap
$27.53M
Enterprise Value$8.13M
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 19, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume122,773
30 Day Avg. Volume180,497
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$39.67Price Target Upside6739.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.92
Revenue Forecast (FY)$6.04M
Bulls Say, Bears Say
Bulls Say
Orphan Drug DesignationOrphan designation confers regulatory incentives (market exclusivity, tax credits, fee reductions) and raises the program’s strategic and commercial value for rare CNS tumors. This materially improves long-term partnership and reimbursement prospects and reduces some regulatory cost risks.
High Gross MarginsVery high reported gross margins indicate favorable underlying product economics for the radiotherapeutic platform if commercialized. Sustained margin potential supports scalable profitability once revenue ramps and makes the asset more attractive to partners or acquirers.
Strengthened Development LeadershipHiring an experienced CDO combined with board additions improves clinical and regulatory execution capability. Strong development leadership increases probability of efficient trial design, clearer regulatory pathways, and stronger partner negotiations over the medium term.
Bears Say
Severe Cash BurnSustained, large negative operating and free cash flow forces reliance on external capital to fund trials and operations. This constrains strategic flexibility, shortens runway absent financing or deals, and elevates execution risk over the next several quarters.
Very Small, Declining RevenueA tiny, falling revenue base means the company lacks product-derived cash to fund development. Until approvals or material partnerships occur, revenue volatility prolongs dependence on financings and undermines near-term trajectory toward sustainable margins and profitability.
Equity Financing / Dilution RiskUse of at-the-market equity programs and historical reverse split (leaving large authorized share pool) signals ongoing dependence on equity capital. Repeated dilution risk can erode shareholder value and increase cost of capital, limiting long-term investor support absent clear milestones.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $27.53M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 37 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
PSTV Stock 12 Month Forecast
Average Price Target
$39.67
▲(6739.08% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
2.91% Insiders
<0.01% Other Institutional Investors
95.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---